Dermatomyositis is an idiopathic inflammatory myopathy with a highly heterogeneous disease course. Although there is a known increase in cancer risk surrounding the time of dermatomyositis diagnosis, the mechanisms driving this increased risk are not well understood. Further, there are no current standardized cancer screening guidelines for dermatomyositis patients. In this issue of the JCI, Fiorentino, Mecoli, et al. discovered additional autoantibodies in patients with dermatomyositis and anti–TIF1-γ autoantibodies, a known risk factor for malignancy. They observed a decreased cancer risk with an increasing number of autoantibodies. Importantly, these findings indicate that more detailed autoantibody phenotyping at diagnosis might better predict cancer risk and also suggest that diversity and kinetics of the host immune response might influence cancer development.

中文翻译：

---

使用自身抗体特征来定义皮肌炎的癌症​​风险


皮肌炎是一种特发性炎症性肌病，具有高度异质性的病程。尽管已知皮肌炎诊断前后癌症风险会增加，但导致这种风险增加的机制尚不清楚。此外，目前还没有针对皮肌炎患者的标准化癌症筛查指南。在本期JCI中，Fiorentino、Mecoli 等人。在皮肌炎和抗 TIF1-γ 自身抗体（已知的恶性肿瘤风险因素）患者中发现了额外的自身抗体。他们观察到随着自身抗体数量的增加，癌症风险降低。重要的是，这些发现表明，诊断时更详细的自身抗体表型可能会更好地预测癌症风险，并且还表明宿主免疫反应的多样性和动力学可能会影响癌症的发展。